DSI
AIMT

Daiwa SB Investments’s Aimmune Therapeutics AIMT Stock Holding History

Daiwa SB Investments’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-51,895
Closed -$1.4M – 268
2018
Q2 		$1.4M Buy
51,895
+26,351
+103% +$806K 0.34% 62
2018
Q1 		$813K Buy
25,544
+18,254
+250% +$642K 0.24% 75
2017
Q4 		$276K Buy
7,290
+3,925
+117% +$127K 0.07% 119
2017
Q3 		$83K Sell
3,365
-1,680
-33% -$36.2K 0.02% 165
2017
Q2 		$104K Sell
5,045
-1,050
-17% -$20K 0.03% 159
2017
Q1 		$132K Buy
+6,095
New +$125K 0.04% 152

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Daiwa SB Investments's AIMT Position: Q3 2018 in Review

Daiwa SB Investments sold out of Aimmune Therapeutics (AIMT) in Q3 2018, closing a stake of 51,895 shares — an estimated $1.4M sold.

Daiwa SB Investments first reported a position in AIMT in Q1 2017 and held it in 6 quarters. The position peaked at $1.4M in Q2 2018. 142 funds tracked by Wall St. Rank hold AIMT as of Q3 2018.

  • Daiwa SB Investments reported no remaining Aimmune Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Daiwa SB Investments sold 51,895 Aimmune Therapeutics shares in Q3 2018, an estimated $1.4M.
  • Daiwa SB Investments first reported a position in Aimmune Therapeutics in Q1 2017 and held it in 6 quarters.
  • Daiwa SB Investments's Aimmune Therapeutics position peaked at $1.4M in Q2 2018.
  • 142 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2018.

Based on Daiwa SB Investments's 13F filing for Q3 2018, filed 10 Oct 2018.